Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.805 +0.175 (+2.64%)
Streaming Delayed Price Updated: 10:46 AM EST, Nov 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 152,452
Open 6.600
Bid (Size) 6.800 (300)
Ask (Size) 6.810 (400)
Prev. Close 6.630
Today's Range 6.580 - 6.885
52wk Range 3.760 - 16.83
Shares Outstanding 93,100,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Q3 Earnings Roundup: Myriad Genetics (NASDAQ:MYGN) And The Rest Of The Therapeutics Segment
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 High-Flying Stock with Solid Fundamentals and 2 We Question
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,... 
Via StockStory
Topics Artificial Intelligence Economy

Performance

YTD
-49.6%
-49.6%
1 Month
-13.9%
-13.9%
3 Month
+23.5%
+23.5%
6 Month
+52.9%
+52.9%
1 Year
-55.3%
-55.3%

More News

Read More
News headline image
Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
The Top 5 Analyst Questions From Myriad Genetics’s Q3 Earnings Call
Via StockStory
Topics Earnings
News headline image
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Why Myriad Genetics (MYGN) Stock Is Down Today
Via StockStory
Topics Economy Government World Trade
News headline image
MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market Headwinds
Via StockStory
News headline image
Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops
Via StockStory
News headline image
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings
Via StockStory
News headline image
Exploring Myriad Genetics's Earnings Expectations ↗
Via Benzinga
News headline image
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Stock Under $10 Worth Your Attention and 2 Facing Challenges
Via StockStory
News headline image
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 Unpopular Stocks That Deserve a Second Chance and 1 That Underwhelm
Via StockStory
News headline image
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Cash-Burning Stocks with Open Questions
Via StockStory
News headline image
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
Via StockStory
Topics Economy Government World Trade
News headline image
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
From D S Simon
Via GlobeNewswire
News headline image
A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unprofitable Stocks That Fall Short
Via StockStory

Frequently Asked Questions

Is Myriad Genetics, Inc. - Common Stock publicly traded?
Yes, Myriad Genetics, Inc. - Common Stock is publicly traded.
What exchange does Myriad Genetics, Inc. - Common Stock trade on?
Myriad Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Myriad Genetics, Inc. - Common Stock?
The ticker symbol for Myriad Genetics, Inc. - Common Stock is MYGN on the Nasdaq Stock Market
What is the current price of Myriad Genetics, Inc. - Common Stock?
The current price of Myriad Genetics, Inc. - Common Stock is 6.805
When was Myriad Genetics, Inc. - Common Stock last traded?
The last trade of Myriad Genetics, Inc. - Common Stock was at 11/19/25 10:46 AM ET
What is the market capitalization of Myriad Genetics, Inc. - Common Stock?
The market capitalization of Myriad Genetics, Inc. - Common Stock is 633.55M
How many shares of Myriad Genetics, Inc. - Common Stock are outstanding?
Myriad Genetics, Inc. - Common Stock has 634M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.